## Design and synthesis of new amino-modified iminocyclitols: selective inhibitors of $\alpha$ -galactosidase<sup>†</sup><sup>‡</sup>§

Muthupandian Ganesan, Rekhawar V. Madhukarrao and Namakkal G. Ramesh\*

Received 11th December 2009, Accepted 2nd February 2010 First published as an Advance Article on the web 15th February 2010 DOI: 10.1039/b926123k

A new and short synthesis of hitherto unreported stereo analogue of amino-modified five-membered iminocyclitols from readily available tri-O-benzyl-D-glucal is described. Significantly, glycosidase inhibition studies of alkylamino substituted iminocyclitols display a high degree of selectivity towards  $\alpha$ -galactosidase.

Over the years, the chemistry and biology of naturally occurring iminocyclitols (azasugars) and their synthetic analogues have received immense research attention due to their significant and selective inhibition of various glycosidases,<sup>1</sup> a feature attributable to their structural resemblance as well as mimicry of the glycosidase oxocarbenium-ion transition state.<sup>2</sup> The successful launch of synthetically modified six-membered azasugar based clinical drugs such as Glyset<sup>®</sup> **2** (for non-insulin dependant diabetes) and Zavesca<sup>®</sup> **3** (for the control of Gaucher's disease) (Fig. 1) has provided an added impetus for research in this area.<sup>3</sup> As a consequence, functional group modifications at the



Fig. 1 Representative examples of azasugars.

aglycon moieties of iminocyclitols, in order to fine tune their inhibitory activities against glycosidases, is becoming an area of increasing importance. Pioneering work on such functional group modifications on five-membered iminocyclitols was carried out by Wong et al. who had observed that a synthetic azasugar 6 obtained by replacement of one of the side chain hydroxyl groups of naturally occurring 2,5-dihydroxymethyl-3,4dihydroxy pyrrolidine (DMDP) 4 by an acetamido group had pronounced inhibitory activity against N-acetylglucosaminidase.4 Subsequently, a high throughput screening of a library of such 1-aminodeoxy-DMDP (ADMDP) analogues, synthesized by them, resulted in the identification of novel structures for antivirals and osteoarthritis.5 Stütz and coworkers have carried out extensive research on the synthesis of C-1 amino-modified five-memebered iminocyclitols such as 5 by meticulously exploiting the Amadori rearrangement of 5-azido-5-deoxy-D-glucofuranose and similar compounds with dibenzylamine as a key step and investigated, in detail, their structure-activity relationship against various glycosidases.<sup>6</sup> Since the significant findings that such synthetically designed azasugars are promising structures for various disorders, there has been an upsurge in research related to their synthesis and biological studies. A recent report on the first structural basis of glycosidase inhibition by five-membered azasugars has further spurred the research activities in this area.2a Besides the glycosidase inhibition activities, transition metal complexes of amino-substituted polyhydroxypyrrolidines have been used as catalysts for asymmetric transformations and find applications in medicines as well.7

A few other strategies so far reported for the synthesis of ADMDP 5 and its various stereoisomers include (i) synthetic manipulations of naturally occurring DMDP 4 and its stereo analogues by way of selective conversion of one of the side chain hydroxyl groups into an amino functionality;5b,8 (ii) intramolecular cyclization of a  $C_2$ -symmetric amino alcohol;<sup>9</sup> (iii) nucleophilic ring opening of sugar based bis-aziridines;<sup>10</sup> (iv) transformation of an optically active  $\gamma$ -lactam in to ADMDP analogues;<sup>11</sup> and (v) nucleophilic addition of cyanide to sugar based cyclic nitrones followed by reduction.7a,12 Postel and co-workers very recently disclosed the synthesis of 2-aminocyclopropyl polyhydroxylated pyrrolidine and its isomers through cyclopropanation of glycoaminonitriles.13 To the best of our knowledge, there is no glycal based approach available for the synthesis of such aminomodified azasugars, despite their ready availability. Earlier we had reported a novel one-pot diamination of glycals with chloramine-T and utilized them for efficient syntheses of N-linked glycoamino acids and peptides.<sup>14</sup> We expected that the pluripotent diamine 8 could as well serve as a versatile precursor for the synthesis of amino-modified azasugar 10, through a cleavage-recombination

Department of Chemistry, Indian Institute of Technology-Delhi, Hauz Khas, New Delhi, 110016, India. E-mail: ramesh@chemistry.iitd.ac.in; Fax: +91-11-26581102; Tel: +91-11-26596584

<sup>†</sup> Dedicated to Prof. Yasuyuki Kita on the occasion of his 65th birthday.
‡ Part of this work was presented as a poster at the 15th European Carbohydrate Symposium held at University of Vienna, Vienna, Austria, 19–24 July 2009.

<sup>§</sup> Electronic supplementary information (ESI) available: Experimental procedure, spectral data, and copies of <sup>1</sup>H-NMR and <sup>13</sup>C-NMR spectra of all compounds; detailed procedure for enzyme assay studies including the source of enzymes, methodology, range of activities. See DOI: 10.1039/b926123k

pathway. In this communication, we report a new and a very short synthesis of a hitherto unreported stereo analogue of ADMDP from readily available tri-O-benzyl-D-glucal 7 via cleavage of the  $O-C_1$  bond of diamine 8 followed by an intramolecular cyclization of the diamino alcohol intermediate 9. The glycosidase inhibition studies of these molecules reveal that azasugars with an alkylamino-substituted side chain display a high degree of selectivity towards  $\alpha$ -galactosidase (from green coffee bean).

Our synthesis of amino-modified iminocyclitols started with the reduction of the readily available diamine  $8^{14}$  to the diamino alcohol 9, which was easily accomplished in 95% yield by refluxing 8 with 1.5 equiv. of LiAlH<sub>4</sub> for 20 min (Scheme 1). It was expected that an intramolecular cyclization of compound 9 could readily provide the pyrrolidine derivative 10. Thus, when compound 9 was initially subjected to an intramolecular cyclization under Mitsunobu conditions, complete consumption of starting material was noticed (TLC) in 30 min and formation of a new product was observed. After purification and thorough characterization, the product was confirmed to be the polyhydroxypyrrolidine 10 and not the piperidine derivative 11 (Scheme 1). In the <sup>1</sup>H-NMR spectrum of the product, the signal of the NH proton (that disappeared upon D<sub>2</sub>O exchange) resonated as a triplet with a coupling constant of 7.2 Hz, thereby indicating that there were two neighbouring protons for the NH to couple with. This clearly established the structure of the product to be the pyrrolidine 10. Both the neighbouring diastereotopic methylene protons were also found to couple with the NH proton as revealed by the <sup>1</sup>H<sup>-1</sup>H COSY spectrum of the above compound. On the other hand, in the case of piperidine derivative 11, the signal of the NH proton was expected to resonate only as a doublet due to its coupling with the lone neighbouring CH proton. Irrespective of the reaction conditions (change in temperature, solvent, time etc.) and other reagents {(PPh<sub>3</sub>, I<sub>2</sub>, imidazole); (NaH, MsCl, THF)} employed, compound 10 was always obtained as the

Scheme 1 Reagents and conditions: (a) LiAlH<sub>4</sub>, THF, reflux, 20 min, 95%; (b) Ph<sub>3</sub>P, DEAD, THF, 0 °C to rt, 30 min, 90%; (c) Na-liq.NH<sub>3</sub>, THF, -78 °C, 3 h, 86%.

exclusive product in the intramolecular reaction of 9. Among them, the best yield (90%) was obtained when the reaction was carried out under Mitsunobu conditions at 0 °C to room temperature with 1.3 equiv. of PPh<sub>3</sub> and 1.4 equiv. of DEAD in THF as a solvent. In order to study the inhibition properties it was imperative to deprotect the tosyl and benzyl groups of 10 to obtain the parent polyhydroxypyrrolidine 12. This was conveniently achieved in a single step by treating compound 10 with Na/liq.NH<sub>3</sub> to obtain (2S,3R,4R,5S)-2-aminomethyl-5hydroxymethyl-3,4-dihydroxypyrrolidine 12 in 86% yield. Thus, we have accomplished a very short synthesis of a new stereo-analogue of ADMDP in just three steps and with a total yield of 74% from 8 (Scheme 1).

We next focused our attention towards the synthesis of a few derivatives of 12, possessing different substituents at the side chain amino functionality, with a view to investigating the role of substituents on their inhibition activities. An obvious choice was the synthesis of the tosyl derivative 15, for which selective deprotection of the tertiary tosyl group of 10 in the presence of the side chain secondary one was an essential requisite. After several experiments, we were successful in chemoselectively deprotecting the tertiary tosyl group of 10 over the secondary one by treating it with Na-Hg. Compound 14 was obtained in 96% yield. Subsequent catalytic hydrogenation of 14 in presence of 10% Pd/C gave the tosylamido polyhydroxypyrrolidine 15 in 90% yield (Scheme 2).



Scheme 2 Reagents and conditions: (a) Ac<sub>2</sub>O, DMAP, pyridine, rt, 24 h, 95%; (b) 3% Na-Hg, Na2HPO4, DMF-MeOH (4:0.5), 60 °C, 3 h; (c) 10% Pd/C, H<sub>2</sub>(g), MeOH, 30 °C, 5 h, 90%.

While a library of compounds bearing diverse functional groups on the side chain nitrogen of ADMDP have been reported in the literature,<sup>4-13</sup> those possessing simple alkyl groups were visibly missing and thus their glycosidase inhibition studies as well as structure-activity relationship largely remain uninvestigated. This prompted us to explore the possibility of synthesizing a few alkyl derivatives of 12 and undertake their inhibitory studies against glycosidases. Thus, reaction of 10 with alkyl halides in presence of sodium hydride afforded the alkyl-substituted derivatives 16 and 17 in good yields. Unexpectedly, global deprotection on compounds 16 and 17 using Na/liq. NH3 did not give the required products 20 and 21. Instead, cleavage of the alkyl groups also occurred along with the other protecting groups resulting in the formation of ADMDP 12, which was rather unusual and



BnO-

NHTs

OBn

BnO

Ref. 14



Scheme 3 *Reagents and conditions*: (a) NaH, RX, DMF, rt; (b) 3% Na–Hg, Na<sub>2</sub>HPO<sub>4</sub>, DMF–MeOH (4:0.5), 60 °C, 3 h; (c) (i) 10% Pd/C, H<sub>2</sub>(g), dil. HCl, MeOH, 30 °C, 12 h, (ii) Et<sub>3</sub>N.

Our next target was the synthesis of the acetyl derivative 22. Acetylation of compound 10 using standard procedures afforded the N-acetyl-N-tosyl derivative 13 in 95% yield (Scheme 2), which however, on treatment with Na-Hg did not undergo the expected didetosylation reaction. Unlike compounds 16 and 18, which underwent smooth didetosylation reaction with Na-Hg, in the case of 13, it was the side chain acetyl and not the tosyl group that was cleaved along with the tosyl group attached to the ring nitrogen to afford compound 14 exclusively (Scheme 2). Such a preference of acetyl over tosyl group cleavage of N-acetyl-N-tosylamides with Na-Hg has hardly been reported in literature and thus could prove to be a useful protocol in organic synthesis. Finally, synthesis of the acetamido polyhydroxypyrrolidine 22 was carried out by direct acetylation of the free amine 12 with acetic anhydride under solvent-free conditions using a modified procedure developed in our lab (Scheme 4).



Scheme 4 Reagents and conditions: (a)  $Ac_2O$ , 0 °C to rt, sonication, 15 min, 85%.

All new compounds were screened for their inhibition activities against four different glycosidases (Table 1). Compound **12** and its acetyl derivative **22** did not show any inhibition against any of these glycosidases. On the other hand, very surprisingly, the tosyl derivative **15** and alkylamino derivatives **20**, **21** gave complementary results. While the tosyl derivative **15** has a broad range of inhibition against  $\alpha$ -glucosidase,  $\beta$ -glucosidase and  $\beta$ -galactosidase, it did

Table 1         Glycosidase inhibition stu	dies
--	------

Enzyme (source)	IC <sub>50</sub> , mM				
	12	15	20	21	22
α-glucosidase type I (baker's yeast) β-glucosidase (almond) α-galactosidase (green coffee beans)	n.i. n.i. n i	3.5 6.3	n.i. n.i. 6 9	n.i. n.i. 8 1	n.i. n.i. n i
$\beta$ -galactosidase (Escherichia coli)	n.i.	5.4	n.i.	n.i.	n.i.

n.i., no inhibition was observed up to 12 mM inhibitor concentration

not inhibit  $\alpha$ -galactosidase. Quite contrastingly, both the alkyl derivatives **20** and **21** displayed a very high degree of selectivity by inhibiting *only*  $\alpha$ -galactosidase among the four glycosidases tested. Thus, the complementary behaviour of **15** *versus* **20** and **21** toward various enzymes is not only interesting but also could provide vital information for further understanding the structural basis of glycosidase inhibition by these amino-modified five-membered iminocyclitols.

In conclusion, we have developed a glycal based route towards the synthesis of a new stereo analogue of amino-modified polyhydroxypyrrolidines. This methodology is one of the shortest (only 3 to 5 steps from the diamine 8) routes available for the synthesis of ADMDP analogues. The glycosidase inhibitory activities of these compounds are quite interesting. Notably, the specific inhibitory nature of alkyl-ADMDP compounds 20 and 21 towards  $\alpha$ -galactosidase is expected to spur further research on the synthesis and biological studies of alkylamino derivatives, which has largely remained elusive so far. Detailed investigation on the nature of the interaction between these inhibitors and the enzymes is currently underway. Further, since inhibitors of  $\alpha$ -galactosidase have been found to be promising chemical chaperones for Fabry's disease,<sup>15</sup> compounds 20 and 21 reported here could find potential applications in this direction as well.

## Acknowledgements

The authors thank the Department of Science and Technology, India for financial support and Dr (Ms) Ruchi Gaur for her help in the enzyme assay studies.

## References

- (a) N. Asano, *Glycobiology*, 2003, **13**, 93R; (b) A. A. Watson, G. W. J. Fleet, N. Asano, R. J. Molyneux and R. J. Nash, *Phytochemistry*, 2001, **56**, 265; (c) *Iminosugars as Glycosidase Inhibitors: Nojirimycin and Beyond*, ed. A. E. Stütz, Wiley-VCH, Weinheim, 1999 and references cited therein.
- 2 (a) M. E. C. Caines, S. M. Hancock, C. A. Tarling, T. M. Wrodnigg, R. V. Stick, A. E. Stütz, A. Vasella, S. G. Withers and N. C. J. Strynadka, *Angew. Chem., Int. Ed.*, 2007, **46**, 4474; (b) J. Wicki, S. J. Williams and S. G. Withers, *J. Am. Chem. Soc.*, 2007, **129**, 4530; (c) V. H. Lillelund, H. H. Jensen, X. Liang and M. Bols, *Chem. Rev.*, 2002, **102**, 515 and references cited in these articles.
- 3 B. G. Winchester, *Tetrahedron: Asymmetry*, 2009, **20**, 645 and references cited therein.
- 4 Y. Takaoka, T. Kajimoto and C.-H. Wong, J. Org. Chem., 1993, 58, 4809.
- 5 (a) P.-H. Liang, W.-C. Cheng, Y.-L. Lee, H.-P. Yu, Y.-T. Wu, Y.-L. Lin and C.-H. Wong, *ChemBioChem*, 2006, **7**, 165; (b) J. Liu, M. M. D. Numa, H. Liu, S.-J. Huang, P. Sears, A. R. Shikhman and C.-H. Wong, *J. Org. Chem.*, 2004, **69**, 6273; (c) J. Liu, A. R. Shikhman, M. K. Lotz and C.-H. Wong, *Chem. Biol.*, 2001, **8**, 701; (d) M. Takebayashi, S. Hiranuma, Y. Kanie, T. Kajimoto, O. Kanie and C.-H. Wong, *J. Org.*

Chem., 1999, **64**, 5280; (e) T. Kajimoto, K. K.-C. Liu, R. L. Pederson, Z. Zhong, Y. Ichikawa, J. A. Porco Jr. and C.-H. Wong, *J. Am. Chem. Soc.*, 1991, **113**, 6187.

- 6 (a) T. M. Wrodnigg, F. Diness, C. Gruber, H. Häusler, I. Lundt, K. Rupitz, A. J. Steiner, A. E. Stütz, C. A. Tarling, S. G. Withers and H. Wölfler, *Bioorg. Med. Chem.*, 2004, **12**, 3485; (b) T. M. Wrodnigg, S. G. Withers and A. E. Stütz, *Bioorg. Med. Chem. Lett.*, 2001, **11**, 1063; (c) A. Hermetter, H. Scholze, A. E. Stütz, S. G. Withers and T. M. Wrodnigg, *Bioorg. Med. Chem. Lett.*, 2001, **11**, 1339; (d) T. M. Wrodnigg, W. Gaderbauer, P. Greimel, H. Häusler, F. K. Sprenger, A. E. Stütz, C. Virgona and S. G. Withers, *J. Carbohydr. Chem.*, 2000, **19**, 975; (e) T. M. Wrodnigg, A. E. Stütz and S. G. Withers, *Tetrahedron Lett.*, 1997, **38**, 5463.
- 7 (a) P. Merino, I. Delso, T. Tejero, F. Cardona, M. Marradi, E. Faggi, C. Parmeggiani and A. Goti, *Eur. J. Org. Chem.*, 2008, 2929 and references cited therein; (b) D.-K. Kim, Y.-W. Kim, H.-T. Kim and K. H. Kim, *Bioorg. Med. Chem. Lett.*, 1996, **6**, 643.

- 8 R. C. Reynolds, N. Bansal, J. Rose, J. Friedrich, W. J. Suling and J. A. Maddry, *Carbohydr. Res.*, 1999, 317, 164.
- 9 S. H. Kang and D. H. Ryu, Tetrahedron Lett., 1997, 38, 607.
- 10 I. McCort, S. Fort, A. Duréault and J.-C. Depezay, *Bioorg. Med. Chem.*, 2000, 8, 135.
- 11 F. Popowycz, S. Gerber-Lemaire, C. Schütz and P. Vogel, *Helv. Chim. Acta*, 2004, 87, 800.
- 12 E.-L. Tsou, Y.-T. Yeh, P.-H. Liang and W.-C. Cheng, *Tetrahedron*, 2009, 65, 93.
- 13 D. Declerck, S. Josse, A. N. V. Nhien and D. Postel, *Tetrahedron Lett.*, 2009, **50**, 2171.
- 14 (a) V. Kumar and N. G. Ramesh, Org. Biomol. Chem., 2007, 5, 3847;
   (b) V. Kumar and N. G. Ramesh, Chem. Commun., 2006, 4952.
- 15 (a) Y. Suzuki, S. Ogawa and Y. Sakakibara, Pers. Med. Chem., 2009, 3, 7; (b) K. Sugawara, Y. Tajima, I. Kawashima, T. Tsukimura, S. Saito, K. Ohno, K. Iwamoto, T. Kobayashi, K. Itoh and H. Sakuraba, Mol. Genet. Metab., 2009, 96, 233.